Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia (Q41657172)

6 October 2017

title

Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia (English)

1 reference

6 October 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Björn A Espedido

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sebastiaan J van Hal

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

17 November 2014

1 reference

Journal of Antimicrobial Chemotherapy

6 October 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

797-801

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

Predictors of mortality in Staphylococcus aureus Bacteremia

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Ceftaroline-heteroresistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU455

21 January 2018

Identifiers

DOI

10.1093/JAC/DKU455

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25406295%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference